Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience

Haematologica

Volumn 90, Issue 8, 2005, Pages 1143-1145

  Laurenti, Luca ^a   Piccioni, Paola ^a   Tarnani, Michela ^a   Efremov, Dimitar G ^b   Fiorini, Akssia ^a   Garzia, Mariagrazia ^a   Sica, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ICGEB Outstation   (Italy)

Author keywords

Chronic lymphocytic leukemia; Immunotherapy; Low dose alemtuzumab

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; NEUTROPENIA; REMISSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 24944566741     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-74.
2. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
3. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
4. Lundin J, Kimby E, Biorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73.
5. Cheson BD, Bennet JM, Greper M, Kay M, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: revised Guidelines for Diagnosis and Treatment. Blood 1996;87:4990-7.
6. Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:1248-52.
7. Laurenti L, Piccioni P, Tarnani M, Chiusolo P, Piccirillo N, Rumi C, et al. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. Leukemia 2005;19:153-4.
8. Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;1:484-90.
9. Cortelezzi, A, Pasquini MC, Sarina B, Bertani G, Grifoni F, Colombi M, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005;90:410-2.